New! Search for patents from more than 100 countries including Australia, Brazil, Sweden and more

WO2013089636A1 - Processes for manufacturing of a kinase inhibitor - Google Patents

Processes for manufacturing of a kinase inhibitor Download PDF

Info

Publication number
WO2013089636A1
WO2013089636A1 PCT/SE2012/051411 SE2012051411W WO2013089636A1 WO 2013089636 A1 WO2013089636 A1 WO 2013089636A1 SE 2012051411 W SE2012051411 W SE 2012051411W WO 2013089636 A1 WO2013089636 A1 WO 2013089636A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
crystalline form
formula
according
described
Prior art date
Application number
PCT/SE2012/051411
Other languages
English (en)
French (fr)
Inventor
Fredrik Lehmann
Ulf Bremberg
Ellen SÖLVER
Johan ERIKSSON BAJTNER
Viveca Thornqvist Oltner
Original Assignee
Akinion Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161570866P priority Critical
Priority to US61/570,866 priority
Application filed by Akinion Pharmaceuticals Ab filed Critical Akinion Pharmaceuticals Ab
Publication of WO2013089636A1 publication Critical patent/WO2013089636A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
PCT/SE2012/051411 2011-12-15 2012-12-17 Processes for manufacturing of a kinase inhibitor WO2013089636A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201161570866P true 2011-12-15 2011-12-15
US61/570,866 2011-12-15

Publications (1)

Publication Number Publication Date
WO2013089636A1 true WO2013089636A1 (en) 2013-06-20

Family

ID=48612949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2012/051411 WO2013089636A1 (en) 2011-12-15 2012-12-17 Processes for manufacturing of a kinase inhibitor

Country Status (1)

Country Link
WO (1) WO2013089636A1 (ko)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060091067A1 (en) * 2004-11-02 2006-05-04 Agouron Pharmaceuticals, Inc. Methods for the removal of heavy metals
WO2009095399A2 (en) * 2008-02-01 2009-08-06 Akinion Pharmaceuticals Ab Pyrazine derivatives and their use as protein kinase inhbitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060091067A1 (en) * 2004-11-02 2006-05-04 Agouron Pharmaceuticals, Inc. Methods for the removal of heavy metals
WO2009095399A2 (en) * 2008-02-01 2009-08-06 Akinion Pharmaceuticals Ab Pyrazine derivatives and their use as protein kinase inhbitors

Similar Documents

Publication Publication Date Title
US6890927B2 (en) Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
WO2012071517A2 (en) Novel crystalline forms
US20120129865A1 (en) Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt
WO2013024104A1 (en) 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor
CN101511829A (zh) 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮的合成
US20110021544A1 (en) Hydrochloride salt of ((1s,2s,4r)-4--2-hydroxycyclopentyl)methyl sulfamate
WO2011086541A1 (en) Novel polymorph of nilotinib monohydrochloride monohydrate
WO2016127074A1 (en) 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
WO2003082857A2 (en) Lansoprazole polymorphs and processes for preparation thereof
WO2013069297A1 (ja) 7-{(3s、4s)-3-[(シクロプロピルアミノ)メチル]-4-フルオロピロリジン-1-イル}-6-フルオロ-1-(2-フルオロエチル)-8-メトキシ-4-オキソ-1、4-ジヒドロキノリン-3-カルボン酸の結晶
WO2012063933A1 (ja) 6,7-不飽和-7-カルバモイルモルヒナン誘導体の結晶およびその製造方法
WO2011146511A1 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2006023676A1 (en) Clopidogrel napsylate salt
WO2013053739A1 (en) Process for preparing factor xa inhibitors
WO2012082972A1 (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
WO2006048296A1 (en) Organic compounds
CN103476770A (zh) 新的阿法替尼盐和多晶型物
WO2014173291A1 (zh) 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
CN102260260A (zh) 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途
WO2005080381A1 (en) New polymorphic forms of ondansetron, processes for preparing them, pharmaceutical compositions containing them and their use as antiemetics
WO2011108953A1 (en) PROCESS FOR PREPARATION OF POLYMORPHIC FORM α AND NEW POLYMORPHIC FORM OF IMATINIB MESYLATE ISOLATED IN THAT PROCESS
CN104803908A (zh) 2-异丙氧基-5-甲基-4-(4-哌啶基)苯胺二盐酸盐的水合物、其制备方法及用途
WO2015127872A1 (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
US9067896B2 (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl) -phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof
WO2014034626A1 (ja) N-[2-({2-[(2S)-2-シアノピロリジン-1-イル]-2-オキソエチル}アミノ)-2-メチルプロピル]-2-メチルピラゾロ[1,5-a]ピリミジン-6-カルボキサミドの結晶

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12857946

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 12857946

Country of ref document: EP

Kind code of ref document: A1